The TB-DILI study
What is the TB-DILI study?
- The aim of the TB-DILI study is to identify the safest and most effective way to restart treatment for patients that have had their TB treatment stopped due to experiencing drug-induced liver injury (DILI).
- We will also determine which re-introduction strategy is most cost-effective for the NHS. It is entirely your decision whether to take part in this study. If you agree to take part, you are free to withdraw at any time without giving a reason. If you choose not to take part, your care will not be affected
Who is organising and funding this study?
The study is being organised by the Nottingham University Hospitals NHS Trust (the Sponsor) and coordinated by the Nottingham Clinical Trials Unit (NCTU). The funding for the study is provided by the National Institute for Health Research (NIHR).
All research in the NHS is looked at by an independent group of people, called a Research Ethics Committee, to protect your interests. This study has been reviewed and given favourable opinion by North East - Tyne and Wear South Research Ethics Committee.
Patients who have previously been treated for TB have helped us plan and design this study. Patients’ representatives are also involved in the teams that oversee the running of the study.
Follow us on Twitter!
Further information for participants
Further information for healthcare professionals